ANXA1 and leishmaniasis: Through a comprehensive series of experiments utilizing ANXA1-deficient mice, as well as agonists and antagonists of FPRs, we delineated a potential mechanism underlying this phenomenon, and have provided novel insights into the involvement of ANXA1 in the immunopathogenesis of leishmaniasis, which may be leveraged in the development of therapeutics for leishmaniasis.